For example, [18F]PI-2620 (Fig. 1A), a structural analogue of [18F]Tauvid, has been evaluated for human PET imaging studies in non-AD tauopathies and has shown the ability to image tau aggregation in patients with suspected PSP and corticobasal syndrome (CBS), a common clinical expression of CBD, but does not provide highly robust PET imaging outcome measures24–26. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.